Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Neurodegeneration
Published in: Molecular Neurodegeneration 1/2015

Open Access 01-12-2015 | Research article

Is L-methionine a trigger factor for Alzheimer’s-like neurodegeneration?: Changes in Aβ oligomers, tau phosphorylation, synaptic proteins, Wnt signaling and behavioral impairment in wild-type mice

Authors: Cheril Tapia-Rojas, Carolina B. Lindsay, Carla Montecinos-Oliva, Macarena S. Arrazola, Rocio M. Retamales, Daniel Bunout, Sandra Hirsch, Nibaldo C. Inestrosa

Published in: Molecular Neurodegeneration | Issue 1/2015

Login to get access

Abstract

Background

L-methionine, the principal sulfur-containing amino acid in proteins, plays critical roles in cell physiology as an antioxidant and in the breakdown of fats and heavy metals. Previous studies suggesting the use of L-methionine as a treatment for depression and other diseases indicate that it might also improve memory and propose a role in brain function. However, some evidence indicates that an excess of methionine can be harmful and can increase the risk of developing Type-2 diabetes, heart diseases, certain types of cancer, brain alterations such as schizophrenia, and memory impairment.

Results

Here, we report the effects of an L-methionine-enriched diet in wild-type mice and emphasize changes in brain structure and function. The animals in our studypresented 1) higher levels of phosphorylated tau protein, 2) increased levels of amyloid-β (Aβ)-peptides, including the formation of Aβ oligomers, 3) increased levels of inflammatory response,4) increased oxidative stress, 5) decreased level of synaptic proteins, and 6) memory impairment and loss. We also observed dysfunction of the Wnt signaling pathway.

Conclusion

Taken together, the results of our study indicate that an L-methionine-enriched diet causes neurotoxic effects in vivo and might contribute to the appearance of Alzheimer’s-like neurodegeneration.
Appendix
Available only for authorised users
Literature
1.
Orgeron ML, Stone KP, Wanders D, Cortez CC, van NT, Gettys TW. The impact of dietary methionine restriction on biomarkers of metabolic health. Prog Mol Biol Transl Sci. 2014;121:351–376.PubMedCentralPubMedCrossRef
2.
Levine RL, Mosoni L, Berlett BS, Stadtman ER. Methionine residues as endogenous antioxidants in proteins. Proc Natl Acad Sci U S A. 1996;93:15036–15040.PubMedCentralPubMedCrossRef
3.
Levine RL, Berlett BS, Moskovitz J, Mosoni L, Stadtman ER. Methionine residues may protect proteins from critical oxidative damage. Mech Ageing Dev. 1999;107:323–332.PubMedCrossRef
4.
Stadtman ER, Moskovitz J, Berlett BS, Levine RL. Cyclic oxidation and reduction of protein methionine residues is an important antioxidant mechanism. Mol Cell Biochem. 2002;234-235:3–9.PubMedCrossRef
5.
Stadtman ER, Moskovitz J, Levine RL. Oxidation of methionine residues of proteins: biological consequences. Antioxid Redox Signal. 2003;5(5):577–82.PubMedCrossRef
6.
Caso G, Garlick PJ. Control of muscle protein kinetics by acid-base balance. Curr Opin Clin Nutr Metab Care. 2005;8(1):73–6.PubMedCrossRef
7.
Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002;76(5):1158S–61.PubMed
8.
Hardy ML, Coulter I, Morton SC, Favreau J, Venuturupalli S, Chiappelli F, et al. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evid Rep Technol Assess (Summ). 2003:1–3.
9.
Garlick PJ. Toxicity of methionine in humans. J Nutr. 2006;136(6 Suppl):1722S–5.PubMed
10.
Toue S, Kodama R, Amao M, Kawamata Y, Kimura T, Sakai R. Screening of toxicity biomarkers for methionine excess in rats. J Nutr. 2006;136:1716S–1721S.PubMed
11.
Koladiya RU, Jaggi AS, Singh N, Sharma BK. Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats. BMC Pharmacol. 2008;8:14.PubMedCentralPubMedCrossRef
12.
Irwin MI, Hegsted DM. A conspectus of research on amino acid requirements of man. J Nutr. 1971;101(4):539–66.PubMed
13.
Millward J. Amino acid requirements in adult man. Am J Clin Nutr. 1990;51(3):492–6.PubMed
14.
15.
Brosnan JT, Brosnan ME. The sulfur-containing amino acids: an overview. J Nutr. 2006;136(6 Suppl):1636S–40.PubMed
16.
Lazzerini P, Capecchi P, Selvi E, Lorenzini S, Bisogno S, Galeazzi M, et al. Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev 2007;7:503–509.CrossRef
17.
Boldyrev AA. Molecular mechanisms of homocysteine toxicity. Biochemistry (Mosc). 2009;74(6):589–98.CrossRef
18.
Hooshmand B, Polvikoski T, Kivipelto M, Tanskanen M, Myllykangas L, Erkinjuntti T, et al. Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. Brain. 2013;136:2707–2716.PubMedCentralPubMedCrossRef
19.
Ingenbleek Y, Kimura H. Nutritional essentiality of sulfur in health and disease. Nutr Rev. 2013;71(7):413–32.PubMedCrossRef
20.
Aune D, Ursin G, Veierod MB. Meat consumption and the risk of type 2 diabetes: a systematic review and meta-analysis of cohort studies. Diabetologia. 2009;52(11):2277–87.PubMedCrossRef
21.
Micha R, Wallace SK, Mozaffarian D. Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. Circulation. 2010;121(21):2271–83.PubMedCentralPubMedCrossRef
22.
Nestoros JN, Ban TA, Lehmann HE. Transmethylation hypothesis of schizophrenia: methionine and nicotinic acid. Int Pharmacopsychiatry. 1977;12(4):215–46.PubMed
23.
Cohen BM, Lipinski JF, Vuckovic A, Prosser E. Blood S-adenosyl-L-methionine levels in psychiatric disorders. Am J Psychiatry. 1982;139:229–231.PubMedCrossRef
24.
Smythies JR, Alarcon RD, Morere D, Monti JA, Steele M, Tolbert LC, et al. Abnormalities of one-carbon metabolism in psychiatric disorders: study of methionine adenosyltransferase kinetics and lipid composition of erythrocyte membranes. Biol Psychiatry. 1986;21:1391–1398.PubMedCrossRef
25.
Goren JL, Stoll AL, Damico KE, Sarmiento IA, Cohen BM. Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacotherapy. 2004;24:1501–1507.PubMedCrossRef
26.
Ringman JM, Coppola G. New genes and new insights from old genes: update on Alzheimer disease. Continuum (Minneap Minn). 2013;19(2 Dementia):358–71.
27.
Stadtman ER, Van Remmen H, Richardson A, Wehr NB, Levine RL. Methionine oxidation and aging. Biochim Biophys Acta. 2005;1703:135–140.
28.
Vuaden FC, Savio LE, Piato AL, Pereira TC, Vianna MR, Bogo MR, et al. Long-term methionine exposure induces memory impairment on inhibitory avoidance task and alters acetylcholinesterase activity and expression in zebrafish (Danio rerio). Neurochem Res. 2012;37:1545–1553.PubMedCrossRef
29.
Hrncic D, Rasic-Markovic A, Stojkovic T, Velimirovic M, Puskas N, Obrenovic R, et al. Hyperhomocysteinemia induced by methionine dietary nutritional overload modulates acetylcholinesterase activity in the rat brain. Mol Cell Biochem. 2014;396:99–105.PubMedCrossRef
30.
Velez-Carrasco W, Merkel M, Twiss CO, Smith JD. Dietary methionine effects on plasma homocysteine and HDL metabolism in mice. J Nutr Biochem. 2008;19:362–370.PubMedCentralPubMedCrossRef
31.
32.
Zhang C, Tian Q, Wei W, Peng J, Liu GP, Zhou X, et al. Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol Aging. 2008;29:1654–1665.PubMedCrossRef
33.
Loureiro S, Heimfarth L, Pelaez Pde L, Vanzin C, Viana L, Wyse A, et al. Homocysteine activates calcium-mediated cell signaling mechanisms targeting the cytoskeleton in rat hippocampus. Int J Dev Neurosci. 2008:447–455.
34.
McCampbell A, Wessner K, Marlatt M, Wolffe C, Toolan D, Podtelezhnikov A, et al. Induction of Alzheimer's-like changes in brain of mice expressing mutant APP fed excess methionine. J Neurochem. 2011;116:82–92.PubMedCrossRef
35.
Sengupta A, Kabat J, Novak M, Wu Q, Grundke-Iqbal I, Iqbal K. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys. 1998;357:299–309.PubMedCrossRef
36.
Zhang C, Wei W, Liu Y, Peng J, Tian Q, Liu G, et al. Hyperhomocysteinemia increases beta-amyloid by enhancing expression of gamma-secretase and phosphorylation of amyloid precursor protein in rat brain. Am J Pathol. 2009;174:1481–1491.PubMedCentralPubMedCrossRef
37.
Mufson EJ, He B, Nadeem M, Perez SE, Counts SE, Leurgans S, et al. Hippocampal proNGF signaling pathways and beta-amyloid levels in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol. 2012;71:1018–1029.PubMedCentralPubMedCrossRef
38.
39.
Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352–357.PubMedCrossRef
40.
41.
Grimble RF. The effects of sulfur amino acid intake on immune function in humans. J Nutr. 2006;136(6 Suppl):1660S–5.PubMed
42.
Perna A, Ingrosso D, De Santo N. Homocysteine and oxidative stress. Amino Acids. 2003;25(3-4):409–17.PubMedCrossRef
43.
McCully K. Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation. Ann Clin Lab Sci. 2009;39(3):219–32.PubMed
44.
Makhro A, Mashkina A, Solenaya O, Trunova O, Kozina L, Arutyunian A, et al. Prenatal hyperhomocysteinemia as a model of oxidative stress of the brain. Bull Exp Biol Med. 2008;146:33–35.PubMedCrossRef
45.
Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry. 2000;57(1):65–73.PubMedCrossRef
46.
Grayson DR, Chen Y, Dong E, Kundakovic M, Guidotti A. From trans-methylation to cytosine methylation: evolution of the methylation hypothesis of schizophrenia. Epigenetics. 2009;4:144–149.PubMedCrossRef
47.
Tueting P, Davis JM, Veldic M, Pibiri F, Kadriu B, Guidotti A, et al. L-methionine decreases dendritic spine density in mouse frontal cortex. Neuroreport. 2010;21:543–548.PubMedCentralPubMedCrossRef
48.
Mukaetova-Ladinska E, Hurt J, Honer WG, Harrington CR, Wischik CM. Loss of synaptic but not cytoskeletal proteins in the cerebellum of chronic schizophrenics. Neurosci Lett. 2002;317:161–165.PubMedCrossRef
49.
Inestrosa NC, Tapia-Rojas C, Griffith TN, Carvajal FJ, Benito MJ, Rivera-Dictter A, et al. Tetrahydrohyperforin prevents cognitive deficit, Aβ deposition, tau phosphorylation and synaptotoxicity in the APPswe/PSEN1ΔE9 model of Alzheimer's disease: a possible effect on APP processing. Translational Psychiatry. 2011;1:9.CrossRef
50.
Toledo EM, Inestrosa NC. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer’s disease. Mol Psychiatry. 2010;15(3):272–85. 228.PubMedCrossRef
51.
Yatsugi S, Yamamoto T, Ohno M, Ueki S. Effect of S-adenosyl-L-methionine on impairment of working memory induced in rats by cerebral ischemia and scopolamine. Eur J Pharmacol. 1989;166:231–239.PubMedCrossRef
52.
Oulhaj A, Refsum H, Beaumont H, Williams J, King E, Jacoby R, et al. Homocysteine as a predictor of cognitive decline in Alzheimer's disease. Int J Geriatr Psychiatry. 2010;25:82–90.PubMed
53.
Inestrosa NC, Arenas E. Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci. 2010;11(2):77–86.PubMedCrossRef
54.
55.
Inestrosa NC, Varela-Nallar L, Grabowski CP, Colombres M. Synaptotoxicity in Alzheimer’s disease: the Wnt signaling pathway as a molecular target. IUBMB Life. 2007;59:316–321.PubMedCrossRef
56.
57.
Cerpa W, Toledo EM, Varela-Nallar L, Inestrosa NC. The role of Wnt signaling in neuroprotection. Drug News Perspect. 2009;22:579–591.PubMedCrossRef
58.
Fortress AM, Schram SL, Tuscher JJ, Frick KM. Canonical Wnt signaling is necessary for object recognition memory consolidation. J Neurosci. 2013;33:12619–12626.PubMedCrossRef
59.
Arrazola MS, Varela-Nallar L, Colombres M, Toledo EM, Cruzat F, Pavez L, et al. Calcium/calmodulin-dependent protein kinase type IV is a target gene of the Wnt/beta-catenin signaling pathway. J Cell Physiol. 2009;221:658–667.PubMedCrossRef
60.
61.
Hodar C, Assar R, Colombres M, Aravena A, Pavez L, Gonzalez M, et al. Genome-wide identification of new Wnt/beta-catenin target genes in the human genome using CART method. BMC Genomics. 2010;11:348.PubMedCentralPubMedCrossRef
62.
Hardy J, Selkoe D. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–6.PubMedCrossRef
63.
Zheng-Fischhofer Q, Biernat J, Mandelkow EM, Illenberger S, Godemann R, Mandelkow E. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur J Biochem. 1998;252:542–552.PubMedCrossRef
64.
Lesné S, Sherman M, Grant M, Kuskowski M, Schneider J, Bennett D, et al. Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain. 2013;136:1383–1398.PubMedCentralPubMedCrossRef
65.
Reyes AE, Chacon MA, Dinamarca MC, Cerpa W, Morgan C, Inestrosa NC. Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss. Am J Pathol. 2004;164:2163–2174.PubMedCentralPubMedCrossRef
66.
67.
Foster MW, McMahon TJ, Stamler JS. S-nitrosylation in health and disease. Trends Mol Med. 2003;9(4):160–8.PubMedCrossRef
68.
69.
Gubandru M, Margina D, Tsitsimpikou C, Goutzourelas N, Tsarouhas K, Ilie M, et al. Alzheimer's disease treated patients showed different patterns for oxidative stress and inflammation markers. Food Chem Toxicol. 2013;S0278-6915:00468–00467.
70.
Vargas JY, Fuenzalida M, Inestrosa NC. In vivo Activation of Wnt Signaling Pathway Enhances Cognitive Function of Adult Mice and Reverses Cognitive Deficits in an Alzheimer’s Disease Model. J Neurosci. 2014;34(6):2191–202.PubMedCrossRef
71.
Morris RG. Episodic-like memory in animals: psychological criteria, neural mechanisms and the value of episodic-like tasks to investigate animal models of neurodegenerative disease. Philos Trans R Soc Lond B Biol Sci. 2001;356(1413):1453–65.PubMedCentralPubMedCrossRef
72.
Zhuo JM, Portugal GS, Kruger WD, Wang H, Gould TJ, Pratico D. Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer's disease. Curr Alzheimer Res. 2010;7:140–149.PubMedCentralPubMedCrossRef
73.
Miller AL. The methionine-homocysteine cycle and its effects on cognitive diseases. Altern Med Rev. 2003;8(1):7–19.PubMed
74.
Troen AM, Lutgens E, Smith DE, Rosenberg IH, Selhub J. The atherogenic effect of excess methionine intake. Proc Natl Acad Sci U S A. 2003;100:15089–15094.PubMedCentralPubMedCrossRef
75.
Selley ML, Close DR, Stern SE. The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer’s disease. Neurobiol Aging. 2002;23(3):383–8.PubMedCrossRef
76.
Nilsson K, Gustafson L, Hultberg B. Relation between plasma homocysteine and Alzheimer’s disease. Dement Geriatr Cogn Disord. 2002;14(1):7–12.PubMedCrossRef
77.
Topal G, Brunet A, Millanvoye E, Boucher JL, Rendu F, Devynck MA, et al. Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin. Free Radic Biol Med. 2004;36:1532–1541.PubMedCrossRef
78.
Sai X, Kawamura Y, Kokame K, Yamaguchi H, Shiraishi H, Suzuki R, et al. Endoplasmic reticulum stress-inducible protein, Herp, enhances presenilin-mediated generation of amyloid beta-protein. J Biol Chem. 2002;277:12915–12920.PubMedCrossRef
79.
Ho P, Ortiz D, Rogers E, Shea T. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res. 2002;70:694–702.PubMedCrossRef
80.
Fuso A, Nicolia V, Cavallaro R, Ricceri L, D'Anselmi F, Coluccia P, et al. B-vitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain S-adenosylmethionine, and enhances PS1 and BACE expression and amyloid-beta deposition in mice. Mol Cell Neurosci. 2008;37:731–746.PubMedCrossRef
81.
Pacheco-Quinto J, Rodriguez de Turco E, DeRosa S, Howard A, Cruz-Sanchez F, Sambamurti K, et al. Hyperhomocysteinemic Alzheimer’s mouse model of amyloidosis shows increased brain amyloid beta peptide levels. Neurobiol Dis. 2006;22:651–656.PubMedCrossRef
82.
James SJ, Melnyk S, Pogribna M, Pogribny IP, Caudill MA. Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr. 2002;132:2361S–2366S.PubMed
83.
Ho P, Collins S, Dhitavat S, Ortiz D, Ashline D, Rogers E, et al. Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem. 2001;78:249–253.PubMedCrossRef
84.
Sontag E, Nunbhakdi-Craig V, Sontag J, Diaz-Arrastia R, Ogris E, Dayal S, et al. Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J Neurosci. 2007;27:2751–2759.PubMedCrossRef
85.
Lipton S, Kim W, Choi Y, Kumar S, D'Emilia D, Rayudu P, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A. 1997;94:5923–5928.PubMedCentralPubMedCrossRef
86.
De Ferrari GV, Chacon MA, Barria MI, Garrido JL, Godoy JA, Olivares G, et al. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry. 2003;8:195–208.PubMedCrossRef
87.
Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, Caruso A, et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci. 2004;24:6021–6027.PubMedCrossRef
88.
89.
Zhang Z, Hartmann H, Do VM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, et al. Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature. 1998;395:698–702.PubMedCrossRef
90.
Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M, Inestrosa NC. Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp Cell Res. 2004;297:186–196.PubMedCrossRef
91.
Purro SA, Dickins EM, Salinas PC. The secreted Wnt antagonist Dickkopf-1 is required for amyloid beta-mediated synaptic loss. J Neurosci. 2012;32(10):3492–8.PubMedCrossRef
92.
Caruso A, Motolese M, Iacovelli L, Caraci F, Copani A, Nicoletti F, et al. Inhibition of the canonical Wnt signaling pathway by apolipoprotein E4 in PC12 cells. J Neurochem. 2006;98:364–371.PubMedCrossRef
93.
De Ferrari G, Papassotiropoulos A, Biechele T, Wavrant De-Vrieze F, Avila M, Major M, et al. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad Sci U S A. 2007;104:9434–9439.PubMedCentralPubMedCrossRef
94.
Liu CC, Tsai CW, Deak F, Rogers J, Penuliar M, Sung YM, et al. Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer’s disease. Neuron. 2014;84:63–77.PubMedCentralPubMedCrossRef
95.
Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088–1093.PubMedCentralPubMedCrossRef
96.
Inestrosa NC, Varela-Nallar L. Wnt signaling in the nervous system and in Alzheimer's disease. J Mol Cell Biol. 2014;6:64–74.PubMedCrossRef
97.
Inestrosa NC, Varela-Nallar L. Wnt signalling in neuronal differentiation and development. Cell Tissue Res. 2015;359:215–223.PubMedCrossRef
98.
Chen J, Park CS, Tang SJ. Activity-dependent synaptic Wnt release regulates hippocampal long term potentiation. J Biol Chem. 2006;281:11910–11916.PubMedCrossRef
99.
Tabatadze N, Tomas C, McGonigal R, Lin B, Schook A, Routtenberg A. Wnt transmembrane signaling and long-term spatial memory. Hippocampus. 2012;22:1228–1241.PubMedCentralPubMedCrossRef
100.
Cerpa W, Godoy JA, Alfaro I, Farias GG, Metcalfe MJ, Fuentealba R, et al. Wnt-7a modulates the synaptic vesicle cycle and synaptic transmission in hippocampal neurons. J Biol Chem. 2008;283:5918–5927.PubMedCrossRef
101.
De Ferrari GV, Inestrosa NC. Wnt signaling function in Alzheimer's disease. Brain Res Brain Res Rev. 2000;33:1–12.PubMedCrossRef
102.
Carvajal F, Zolezzi J, Tapia-Rojas C, Godoy J, Inestrosa N. Tetrahydrohyperforin decreases cholinergic markers associated with amyloid-β plaques, 4-hydroxynonenal formation, and caspase-3 activation in AβPP/PS1 mice. J Alzheimers Dis. 2013;36:99–118.PubMed
103.
Cancino GI, Toledo EM, Leal NR, Hernandez DE, Yevenes LF, Inestrosa NC, et al. STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's beta-amyloid deposits. Brain. 2008;131:2425–2442.PubMedCrossRef
104.
Varela-Nallar L, Grabowski CP, Alfaro IE, Alvarez AR, Inestrosa NC. Role of the Wnt receptor Frizzled-1 in presynaptic differentiation and function. Neural Dev. 2009;4:41.PubMedCentralPubMedCrossRef
105.
Inestrosa N, Carvajal F, Zolezzi J, Tapia-Rojas C, Serrano F, Karmelic D, et al. Peroxisome proliferators reduce spatial memory impairment, synaptic failure, and neurodegeneration in brains of a double transgenic mice model of Alzheimer's disease. J Alzheimers Dis. 2013;33:941–959.PubMed
Metadata
Title
Is L-methionine a trigger factor for Alzheimer’s-like neurodegeneration?: Changes in Aβ oligomers, tau phosphorylation, synaptic proteins, Wnt signaling and behavioral impairment in wild-type mice
Authors
Cheril Tapia-Rojas
Carolina B. Lindsay
Carla Montecinos-Oliva
Macarena S. Arrazola
Rocio M. Retamales
Daniel Bunout
Sandra Hirsch
Nibaldo C. Inestrosa
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Molecular Neurodegeneration / Issue 1/2015
Electronic ISSN: 1750-1326
DOI
https://doi.org/10.1186/s13024-015-0057-0

Other articles of this Issue 1/2015

Molecular Neurodegeneration 1/2015 Go to the issue

Research article

Making (anti-) sense out of huntingtin levels in Huntington disease

Erratum

Erratum to: Endogenous TDP-43, but not FUS, contributes to stress granule assembly via G3BP

Methodology

An automated image analysis method to measure regularity in biological patterns: a case study in a Drosophila neurodegenerative model

Research article

Lazarillo-related Lipocalins confer long-term protection against type I Spinocerebellar Ataxia degeneration contributing to optimize selective autophagy

Research article

Region-specific dendritic simplification induced by Aβ, mediated by tau via dysregulation of microtubule dynamics: a mechanistic distinct event from other neurodegenerative processes

Research article

STIM2 protects hippocampal mushroom spines from amyloid synaptotoxicity